Company Research Report: Terapet SA

Company Overview

• Name: Terapet SA

• Mission: Terapet aims to leverage its innovative platform technology to develop integrated imaging solutions, enhancing proton therapy, nuclear imaging, and precision medicine.

• Foundation: No information is available on the founding year and founders.

• Key People: No information is available on key personnel.

• Headquarters: Rue du Pré-Bouvier 7, 1242 Satigny, Geneva, Switzerland.

• Number of Employees: No information is available on the number of employees.

• Revenue: No information is available on the company's revenue.

• Company Focus: Known for next-generation imaging technology that advances nuclear and precision medicine, particularly in proton therapy.

Products

Qualyscan®

• Description: An all-in-one solution designed for mastering quality control in Proton Therapy.

• Key Features:

• End-to-End Quality Assurance Device.

• Capability for 3D dose measurements.

Nuclyscan™

• Description: No specific description provided, but mentioned in the context of future plans.

• Key Features: No detailed features provided.

Recent Developments

• Installations and Testing:

• Successful installation and proton beam testing of Qualyscan® at Skandion Clinic, Sweden in October 2023.

• Successful installation and carbon ion beam testing of Qualyscan® at Yonsei Cancer Center, South Korea in September 2024.

• Product Launches: No new product launches mentioned other than Qualyscan®.

• New Features: No specific mention of new features added to existing products.

• Partnerships: No information is available on new partnerships.

Summary

Terapet SA is a Geneva-based MedTech company, originated from CERN, focused on advancing imaging solutions in nuclear and precision medicine. The company's flagship product, Qualyscan®, offers a comprehensive solution for quality control in proton therapy, marking significant installations in Sweden and South Korea. While specific financial and personnel details remain undisclosed, Terapet SA's strategic direction involves enhancing clinical nuclear imaging and proton therapy technologies. The company remains committed to improving the diagnosis and treatment process in radiotherapy and precision medicine.